Actinomycin D is a protein (RNA transcription) synthesis inhibitor with numerous side-effects, particularly thrombocytopenia which have limited its use.
Actinomycin-D is an antitumor antibiotic with a mechanism of action similar to that of doxorubicin. Unlike doxorubicin, actinomycin-D is relatively inexpensive and has not been associated with cardiac toxicoses.
The efficacy of actinomycin-D as a single agent in the treatment of lymphoma has received limited evaluation, but used as a sole chemotherapy drug has shown some benefits, with prolonged survival in some cases.
Recommended dose in dogs is 0.7 - 0.9 mg/m2 every 3 weeks intravenously.
- Bannink EO et al (2008) Actinomycin D as rescue therapy in dogs with relapsed or resistant lymphoma: 49 cases (1999--2006). J Am Vet Med Assoc 233(3):446-451
- Dervisis NG et al (2007) Efficacy of temozolomide or dacarbazine in combination with an anthracycline for rescue chemotherapy in dogs with lymphoma. J Am Vet Med Assoc 231(4):563-569
- Stewart CF, Ratain MJ. (1997) Topoisomerase interactive agents. In: DeVita Jr VT, Hellman S, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology. vol. 1. Philiadelpia: Lippincott-Raven, pp:452–465
- Khanna C, et al (1998) Randomized controlled trial of doxorubicin versus dactinomycin in a multiagent protocol for treatment of dogs with malignant lymphoma. J Am Vet Med Assoc 213:985–990